BRD4 and adenoid cystic carcinoma: Adenoid cystic carcinoma organoid studies revealed the superior efficacy of proteolysis-targeting chimera dBET6 (targeting Bromodomain-Containing Protein 4 [BRD4]) when compared to conventional inhibitor JQ1, particularly in myoepithelial-rich tumors [66].